P1097 / Raltegravir PK Study

P1097 is a Phase 0, multi-center washout pharmacokinetic trial of raltegravir in infants born to HIV-infected pregnant women. The study is designed to determine the washout pharmacokinetics and safety of in utero/intrapartum exposure following the infants for up to 20 weeks after birth.